Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL

Belzutifan was recently approved for the management of Von Hippel–Lindau disease (VHL). Given the morbidity of recurrent treatment, systemic therapy to reduce or eliminate the need for surgery has been long-awaited. Herein, we sought to gain insight about future utilization by surveying VHL kidney c...

Descripción completa

Detalles Bibliográficos
Autores principales: Arevalo, Aileen, Patel, Neal, Muraki, Peter, Ohtake, Shinji, Bratslavsky, Gennady, Clark, Chandra, Mann, Joshua, Iliopoulos, Othon, Jonasch, Eric, Srinivasan, Ramaprasad, Shuch, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Codon Publications 2022
Materias:
VHL and VHL-related Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551368/
https://www.ncbi.nlm.nih.gov/pubmed/36310638
http://dx.doi.org/10.15586/jkcvhl.v9i3.245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551368/
https://www.ncbi.nlm.nih.gov/pubmed/36310638
http://dx.doi.org/10.15586/jkcvhl.v9i3.245

Ejemplares similares